Subgroup A Nepoviruses

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

3 hours ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

Sanofi tempers its OX40 expectations in asthma after mid-stage miss

3 months ago talkbio0Tagged Amlitelimab, Asthma, exacerbations, Expectations, sanofi, Subgroup A Nepoviruses, TNFRSF4 gene

Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations

Alzheon Investigates Subgroup Data Following Phase 3 Trial of ALZ-801 in Alzheimer’s Disease

3 months ago talkbio0Tagged ALZ-801, Alzheimer 's disease, Amyloid-targeting therapy, Apolipoprotein E4, Genotype, Mental deterioration, Mild cognitive disorder, Phase 3 trial, Precision Medicine, Subgroup A Nepoviruses, Valiltramiprosate

Alzheimer’s disease , ALZ-801 , Valiltramiprosate , APOE4 genotype , Mild cognitive impairment (MCI) , Amyloid-targeting therapy , Phase 3 trial results , Cognitive decline , Subgroup analysis , Precision medicine